Drug Profile
Research programme: factor Xa inhibitors - Catalent/Endotis Pharma
Alternative Names: EP 37; EP 37151Latest Information Update: 03 Oct 2015
Price :
$50
*
At a glance
- Originator Endotis Pharma
- Developer Catalent Pharma Solutions; Endotis Pharma
- Class Oligosaccharides
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 02 Mar 2011 Preclinical development is ongoing in France